This glossary aims to familiarize you with some of the terminology used in Health Technology Assessments (HTAs). HTAs evaluate new drugs and devices in relation to cost, efficacy, utilization, etc., and their future impact on social, ethical, and legal systems. This is a growing field and is central to government policymaking for new technologies.
The purchase cost of a drug to an agency, person, or institution.
Occurs when, given the existing income distribution, resources cannot be reallocated so that they make one person better off (in terms of gaining greater satisfaction from the goods and services they consume) without making at least one other person worse off. This is also known as Pareto efficient.
Total cost divided by the number of units of output.
Anything that results in that is of value.
The cost to purchase the major capital assets required by the programme (for example, equipment, buildings, and land).
A fixed amount of payment per patient, per year, regardless of the volume or cost of services each patient requires.
The application of interventions which have been shown to be efficacious to appropriate patients in a timely fashion to improve patients’ outcomes and value for the use of resources.
The economic definition of cost (also known as opportunity cost) is the value of opportunity forgone, strictly the best opportunity forgone, as a result of engaging resources in an activity. Note that there can be a cost without the exchange of money. Also, the economists’ notion of cost extends beyond the cost falling on the health service alone (e.g., includes costs falling on other services and on patients themselves).
Cost-benefit analysis (CBA)
Expresses all gains and sacrifices in common units (usually money), allowing a judgment to be made of whether, or to what extent, an objective should be pursued.
Cost consequences analysis (CCA)
A form of economic evaluation where the whole array of outputs are presented alongside the costs, without any attempt to aggregate the outputs.
Cost-effectiveness analysis (CEA)
Focuses on the best way of meeting a stated objective given that some means of pursuing it is going ahead. The objective of the programme is not being, and cannot be, questioned.
Cost minimization analysis (CMA)
The consequences of competing interventions are identical, so the comparison can be made on the basis of resource costs alone. The aim is to determine the lowest-cost way of achieving the same outcome.
Cost of illness study
Aims to identify and measure the total costs attributable to a particular disease. These are not a type of economic evaluation as they are not used to assess the costs and benefits of alternative interventions or programmes. They may provide useful information that can be used in the context of an economic evaluation of interventions related to the disease category, although care must be taken as not all costs included in a cost of illness study represent resource costs. Cost of illness studies may also be utilized in the estimation of the economic burden of disease.
Cost-utility analysis (CUA)
A form of cost-effectiveness analysis where benefits are measured in terms of a utility measure such as the quality-adjusted life year (QALY).
Explicit quantitative approach for prescribing conditions under conditions of uncertainty.
The quantity of good buyers wishes to purchase at each conceivable price.
All resources that are consumed in the provision of a health promotion programme. These may be incurred by the health promotion service, community, or clients.
The rate is chosen to express the strength of preference over the timing of costs and benefits (see ‘Discounting’ and ‘Time preference’).
The most widely accepted method of incorporating time preference (see below) into the evaluation of a programme when the costs and benefits do not occur at the same point in time.
The effort of two or more parties to secure the business of a third party by offering, usually under fair or equitable rules of business practice, the most favorable terms.
Economic evaluation (economic appraisal)
The comparison of alternative courses of action in terms of their costs and consequences, with a view to making a choice.
The extent to which programmes achieve their objectives, in real-life settings.
The effect of an intervention under ideal conditions, with participants, fully complying with the programme.
Maximizing the benefit to any resource expenditure, or minimizing the cost of any achieved benefit.
Equal shares of some good or service.
Fair distribution of resources or benefits among different individuals or groups.
Allocates a total budget to specific services according to rules.
Gross employment cost
The total cost of employing an individual (i.e., gross salary, plus National Insurance and Superannuation).
The study of how scarce resources are allocated among alternative uses for the care of sickness and the promotion, maintenance, and improvement of health, including the study of how health care and health-related services, their costs and benefits, and health itself are distributed among individuals and groups in society.
These relate to specific outputs and outcomes resulting from a programme.
Health status index
An index that uses weights to compare different levels of health status and used in the derivation of quality-adjusted life years (QALYs; see below).
Health status measure
A single instrument that measures different aspects of health-related quality of life.
Health years equivalent (HYE)
The hypothetical number of years spent in perfect health that is considered comparable to the actual number of years spent in a particular state of health. These have been suggested as an alternative to quality-adjusted life years (QALYs; see below). The advantage of HYEs is that they fully represent individual preferences without imposing restrictive assumptions associated with QALYs. HYEs are measured using a two-stage gamble technique where the health state is described to the respondent, along with the duration of the state, and the respondent is asked how many years of life in full health would be equivalent to this scenario.
The difference between the cost of treatment and the cost of the comparison treatment.
Incremental cost-effectiveness ratio (ICER)
Obtained by dividing the difference between the costs of the two interventions by the difference in the outcomes (i.e., the extra cost per extra unit of effect).
These relate to the losses to society incurred as a result of participating in the programme, such as the impact on production, domestic responsibilities, and social and leisure activities.
These relate to issues such as improvements in health and well-being and/or quality of life.
These relate to issues such as anxieties and impact on quality of life resulting from participation in the programme. These are generally difficult to measure and value and are often not included in the construction of the cost profile of an economic evaluation.
The last unit of production or consumption, although often relates to change of more than one unit.
The evaluation of the change in costs and benefits produced by a change in the production or consumption of one unit. Less formally it is often used to refer to the change in costs and benefits produced by the particular change in scale of production or consumption which is under consideration.
The extra benefit obtained when output is increased by one unit.
The extra cost that results when output is increased by one unit.
A particular type of decision analysis that allows for the transfer between different health states over a period of time.
An estimate is made for each element of resource use within the programme and a unit cost is derived for each.
The cost of a unit of a resource is the benefit that would be derived from using it in its best alternative use.
The results and value of the intervention ﹘ e.g., intermediate measures such as a number of quitters, or long-term outcomes such as life-years saved.
The activities that result from the use of resources in the programme ﹘ e.g., number and type of materials given, number of client-professional contacts, and their type.
The point of view from which analysis is carried out. The social welfare perspective considers costs and benefits from the point of view of society.
The value today of future costs or benefits (after adjusting by discounting).
Quality-adjusted life years (QALYs)
Calculated by adjusting the estimated number of life-years an individual is expected to gain from an intervention for the expected quality of life in those years. The quality of life score will range between 0 for death, to 1 for perfect health, with negative scores being allowed for states considered worse than death.
Things that contribute to the production of output. Money gives command over resources but is not a resource per se.
There will never be enough resources to satisfy human wants completely.
A process through which the robustness of an economic model is assessed by examining the changes in the results of the analysis when key variables are varied over a specified range.
Refers to a situation where the benefits to those that gain from the reallocation of resources are greater than the losses incurred by those who are made worse off, such that the gainers could compensate the losers and still be better off.
These relate to changes in life expectancy that may result from the programme and measures such as life years saved and lives saved.
Assesses the best way of achieving a given objective. An output is maximized for a given cost, or the costs of producing a given output are minimized.
Individuals are not indifferent to the timing of costs and benefits, preferring benefits sooner and costs later.
A measure of the ‘satisfaction’ (benefit) obtained from consuming goods and services.
In an attempt to generate measures which can be used to compare outcomes across all healthcare interventions, considerable effort has been invested in measures of health status and utility.
Willingness to pay
This technique asks people to state explicitly the maximum amount they would be willing to pay to receive a particular benefit. It is based on the premise that the maximum amount of money an individual is willing to pay for a commodity is an indicator of the value to them of that commodity.
- Batstone G, Edwards M. Achieving clinical effectiveness: just another initiative or a real change in working practice? J Clin Effect 1996;1:19–21.